Patient-Specific Variables Determine the Extent of Cellular Senescence Biomarkers in Ovarian Tumors In Vivo
Abstract
:1. Introduction
2. Materials and Methods
2.1. Chemicals
2.2. Ovarian Tumors
2.3. Histochemistry and Immunolabeling for Markers of Senescence and Proliferation
2.4. Planimetric Analysis
2.5. Statistics
3. Results
3.1. Ovarian Tumors Display Heterogeneous Expression of Senescence Biomarkers in Vivo
3.2. Patient-Specific Determinants of SA-β-Gal in Cancer Cells in Vivo
3.3. Patient-Specific Determinants of γ-H2A.X in Cancer Cells In Vivo
3.4. Patient-Specific Determinants of Ki67 in Cancer Cells In Vivo
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Schosserer, M.; Grillari, J.; Breitenbach, M. The Dual Role of Cellular Senescence in Developing Tumors and Their Response to Cancer Therapy. Front. Oncol. 2017, 7, 278. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Saleh, T.; Bloukh, S.; Carpenter, V.J.; Alwohoush, E.; Bakeer, J.; Darwish, S.; Azab, B.; Gewirtz, D.A. Therapy-Induced Senescence: An “Old” Friend Becomes the Enemy. Cancers 2020, 12, 822. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mikuła-Pietrasik, J.; Niklas, A.; Uruski, P.; Tykarski, A.; Książek, K. Mechanisms and significance of therapy-induced and spontaneous senescence of cancer cells. Cell. Mol. Life Sci. 2020, 77, 213–229. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jelovac, D.; Armstrong, D.K. Recent progress in the diagnosis and treatment of ovarian cancer. CA A Cancer J. Clin. 2011, 61, 183–203. [Google Scholar] [CrossRef] [PubMed]
- Lukanova, A.; Lundin, E.; Toniolo, P.; Micheli, A.; Akhmedkhanov, A.; Rinaldi, S.; Muti, P.; Lenner, P.; Biessy, C.; Krogh, V.; et al. Circulating levels of insulin-like growth factor-I and risk of ovarian cancer. Int. J. Cancer 2002, 101, 549–554. [Google Scholar] [CrossRef]
- Rader, J.S.; Neuman, R.J.; Brady, J.; Babb, S.; Temple, S.; Kost, E.; Mutch, D.G.; Herzog, T.J. Cancer among first-degree relatives of probands with invasive and borderline ovarian cancer. Obstet. Gynecol. 1998, 92, 589–595. [Google Scholar]
- Mikuła-Pietrasik, J.; Uruski, P.; Sosińska, P.; Maksin, K.; Piotrowska-Kempisty, H.; Kucińska, M.; Murias, M.; Szubert, S.; Woźniak, A.; Szpurek, D.; et al. Senescent peritoneal mesothelium creates a niche for ovarian cancer metastases. Cell Death Dis. 2016, 7, e2565. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pakuła, M.; Mały, E.; Uruski, P.; Witucka, A.; Bogucka, M.; Jaroszewska, N.; Makowska, N.; Niklas, A.; Moszyński, R.; Sajdak, S.; et al. Deciphering the Molecular Mechanism of Spontaneous Senescence in Primary Epithelial Ovarian Cancer Cells. Cancers 2020, 12, 296. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Matjusaitis, M.; Chin, G.; Sarnoski, E.A.; Stolzing, A. Biomarkers to identify and isolate senescent cells. Ageing Res. Rev. 2016, 29, 1–12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dimri, G.P.; Lee, X.; Basile, G.; Acosta, M.; Scott, G.; Roskelley, C.; Medrano, E.E.; Linskens, M.; Rubelj, I.; Pereira-Smith, O.; et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 1995, 92, 9363–9367. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Coppe, J.P.; Patil, C.K.; Rodier, F.; Sun, Y.; Munoz, D.P.; Goldstein, J.; Nelson, P.S.; Desprez, P.Y.; Campisi, J. Senes-cence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS. Biol 2008, 6, 2853–2868. [Google Scholar] [CrossRef] [PubMed]
- Jeyapalan, J.C.; Sedivy, J.M. Cellular senescence and organismal aging. Mech. Ageing Dev. 2008, 129, 467–474. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Berek, J.S.; Kehoe, S.T.; Kumar, L.; Friedlander, M. Cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynecol. Obstet. 2018, 143, 59–78. [Google Scholar] [CrossRef] [PubMed]
- Smolle, E.; Taucher, V.; Haybaeck, J. Malignant ascites in ovarian cancer and the role of targeted therapeutics. Anticancer. Res. 2014, 34, 1553–1561. [Google Scholar] [PubMed]
- Sosinska, P.; Mikula-Pietrasik, J.; Ryzek, M.; Naumowicz, E.; Ksiazek, K. Specificity of cytochemical and fluorescence methods of senescence-associated beta-galactosidase detection for ageing driven by replication and time. Biogerontology 2014, 15, 407–413. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mikula-Pietrasik, J.; Sosinska, P.; Janus, J.; Rubis, B.; Brewinska-Olchowik, M.; Piwocka, K.; Ksiazek, K. Bystander senescence in human peritoneal mesothelium and fibroblasts is related to thrombospondin-1-dependent activation of transforming growth factor-beta1. Int. J. Biochem. Cell Biol. 2013, 45, 2087–2096. [Google Scholar] [CrossRef] [PubMed]
- Mikuła-Pietrasik, J.; Uruski, P.; Pakuła, M.; Maksin, K.; Szubert, S.; Woźniak, A.; Naumowicz, E.; Szpurek, D.; Tykarski, A.; Książek, K. Oxidative stress contributes to hepatocyte growth factor-dependent pro-senescence activity of ovarian cancer cells. Free. Radic. Biol. Med. 2017, 110, 270–279. [Google Scholar] [CrossRef] [PubMed]
- Mikula-Pietrasik, J.; Uruski, P.; Matuszkiewicz, K.; Szubert, S.; Moszynski, R.; Szpurek, D.; Sajdak, S.; Tykarski, A.; Ksiazek, K. Ovarian cancer-derived ascitic fluids induce a senescence-dependent pro-cancerogenic phenotype in normal peritoneal mes-othelial cells. Cell Oncol. 2016, 39, 473–481. [Google Scholar] [CrossRef] [PubMed]
- Mikuła-Pietrasik, J.; Uruski, P.; Szubert, S.; Moszyński, R.; Szpurek, D.; Sajdak, S.; Tykarski, A.; Książek, K. Biochemical composition of malignant ascites determines high aggressiveness of undifferentiated ovarian tumors. Med Oncol. 2016, 33, 94. [Google Scholar] [CrossRef] [PubMed]
- Nuovo, G. False-positive results in diagnostic immunohistochemistry are related to horseradish peroxidase conjugates in commercially available assays. Ann. Diagn. Pathol. 2016, 25, 54–59. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Number | Age [Mean (Range)] | |
---|---|---|
All patients (FIGO I-IV) | 24 | 54.9 (28–83) |
FIGO I-II | 11 | 51.9 (29–83) |
FIGO III-IV | 13 | 57.5 (28–77) |
Malignant ascites—YES | 14 | 52.1 (29–74) |
Malignant ascites—NO | 10 | 57.0 (28–83) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Uruski, P.; Mikuła-Pietrasik, J.; Naumowicz, E.; Kaźmierczak, K.; Gaiday, A.N.; Królak, J.; Nowakowski, B.; Moszyński, R.; Tykarski, A.; Książek, K. Patient-Specific Variables Determine the Extent of Cellular Senescence Biomarkers in Ovarian Tumors In Vivo. Biomedicines 2021, 9, 330. https://doi.org/10.3390/biomedicines9040330
Uruski P, Mikuła-Pietrasik J, Naumowicz E, Kaźmierczak K, Gaiday AN, Królak J, Nowakowski B, Moszyński R, Tykarski A, Książek K. Patient-Specific Variables Determine the Extent of Cellular Senescence Biomarkers in Ovarian Tumors In Vivo. Biomedicines. 2021; 9(4):330. https://doi.org/10.3390/biomedicines9040330
Chicago/Turabian StyleUruski, Paweł, Justyna Mikuła-Pietrasik, Eryk Naumowicz, Kamila Kaźmierczak, Andrey N. Gaiday, Jan Królak, Błażej Nowakowski, Rafał Moszyński, Andrzej Tykarski, and Krzysztof Książek. 2021. "Patient-Specific Variables Determine the Extent of Cellular Senescence Biomarkers in Ovarian Tumors In Vivo" Biomedicines 9, no. 4: 330. https://doi.org/10.3390/biomedicines9040330